Trevena, a clinical stage pharmaceutical company in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, said the U.S. Patent and Trademark Office has granted Trevena a composition of matter patent covering its development product TRV027.
TRV027 is an experimental intravenous drug for the treatment of acute decompensated heart failure (ADHF), currently in mid-stage clinical trials. It is a novel beta-arrestin biased ligand of the angiotensin II type 1 receptor that combines the proven benefits of angiotensin blockade with new beta-arrestin-mediated biology to preserve cardiac and renal function.
Trevena entered into a collaborative licensing option agreement for the development of TRV027 with Forest Laboratories. The company expects to commence a 500-patient, multi-center phase IIb clinical trial for TRV027 in ADHF patients by the end of 2013.